Zibb.com: Elan Corporation Plc (Industry News & Blogs)

ITRI signs agreement with AUO and Elan for flexible e-paper devel...

Tue, 24 Nov 2009 07:12:31 GMT

Taiwan's Industrial Technology Research Institute (ITRI) has signed an agreement with AU Optronics (AUO) and Elan Microelectronics to co-develop flexible e-paper and touchscreen flexible e-paper technologies.

Directory of UK Network Installation Companies & Services: Page 2

Sun, 22 Nov 2009 13:09:42 GMT

Directory of Approved network cabling installation companies. Browse through a range of network cabling installation firms, or sign up and get your own network cabling installation company listed (subject to Approval).

Elan Ships D12 Amp; Announces D16 Amp for 2010

Thu, 19 Nov 2009 20:11:23 GMT

The D12 is a 12-channel amplifier that delivers 115 watts at 4 ohms into each channel.

Tysabri, the MS Drug Haunted by Deadly Side Effect, Doesn’t Look ...

Thu, 19 Nov 2009 11:00:34 GMT

Few doctors knew much about a rare brain infection called PML back in 2005, when two patients on a hot new multiple sclerosis drug from Biogen Idec and Elan

Elan Corporation, plc - Pharmaceuticals & Healthcare - Deals and ...

Mon, 16 Nov 2009 11:20:55 GMT

Biotechnology and Pharmaceutical Industry Search Find Companies, News, Events, Jobs, Directory

Elan to Present at Lazard Capital Markets Annual Healthcare Confe...

Fri, 13 Nov 2009 00:21:06 GMT

Elan Corp. has announced that it will present at the Lazard Capital Markets 6th Annual Healthcare Conference, on Tuesday, November 17, at 9:55 a.m. Eastern Time and 2:55 p.m. GMT. Interested parties may access a live audio web cast of the presentation by visiting the Investor Relations section of

Elan to Present at Lazard Capital Markets 6th Annual Healthcare C...

Tue, 10 Nov 2009 21:44:00 GMT

DUBLIN, Ireland--(BUSINESS WIRE)--Elan Corporation, plc (NYSE: ELN - News) today announced that it will present at the Lazard Capital

Elan Corporation PLC , Biogen Idec, Inc. (Massachusetts) Change T...

Tue, 10 Nov 2009 12:00:00 GMT

Reuters -- Ireland's Elan (ELN.I) and U.S. drugmaker Biogen Idec (BIIB.O) have amended the label of their multiple sclerosis drug Tysabri to reflect the increased risk of contracting a potentially deadly brain infection, Elan said in a statement on Saturday.

Elan device provides SDIO port via USB interface

Tue, 10 Nov 2009 08:00:00 GMT

Elan Digital Systems has released its VUB300 connectivity device, providing a single SD/SDIO port via a USB 2.0 system interface.

Elan Digital releases new VUB300 USB to SDIO Host Bridge Chip : E...

Mon, 09 Nov 2009 00:00:00 GMT

Elan Digital releases USB-to-SDIO Host Bridge Chip : Electronics News from Electronic Specifier

Elan Digital Releases New USB-to-SDIO Host Bridge Chip

Fri, 06 Nov 2009 01:08:24 GMT

FAREHAM, UK -- (MARKET WIRE) -- Nov 05, 2009 -- Elan Digital Systems, specialist innovators inSDIO design, announce the release of its latest conn

4-Star Stocks Poised to Pop: Elan

Mon, 26 Oct 2009 13:50:03 GMT

The Motley Fool - Market-trouncing returns could be written in these four stars.

Elan hit by Tysabri questions

Sat, 24 Oct 2009 02:00:00 GMT

The latest drugs, healthcare and pharmaceutical news from the Financial Times, with expert company and industry analysis on FT.com

Biogen, Elan shares plummet on new Tysabri review - Reuters

Fri, 23 Oct 2009 17:22:21 GMT

* European regulators to review risk, benefit of Tysabri * Review follows reports of 23 cases of PML worldwide * Shares of Biogen down 5.5 pct; Elan shares fall 20 pct (Updates share prices) By

STOCKS NEWS US-Biogen, Elan down on new review of Tysabri

Fri, 23 Oct 2009 16:56:00 GMT

Stocks on the move Real Frankfurt: BJU F - news -time Equity news U S stock market report 1234 ET 23Oct2009-Biogen Elan Dublin: DRX IR - news down on new review of Tysabri --------------------------------------------------------------------------- Shares of Biogen Idec NASDAQ: BIIB - news and Elan

Biogen, Elan fall; Dr. Reddy's rallies

Fri, 23 Oct 2009 14:38:00 GMT

Partners Biogen Idec and Elan Corp. lead drug stocks lower in early activity as shares of the companies fall on news that European regulators are reviewing the safety of their multiple sclerosis drug Tysabri.

Tysabri sales lift Elan revenues

Wed, 21 Oct 2009 07:07:14 GMT

Athlone-based pharmaceutical group Elan has today reported net income of $52.3 million for its fiscal third quarter compared to a loss of $83.5 million last year.

Elan Swings to Third-Quarter Profit (at TheStreet.com)

Wed, 21 Oct 2009 06:46:24 GMT

The Irish drugmaker swung to third-quarter net income of $52.3 million, or 11 cents a share, as sales of its Tysabri drug rose.. Check out TheStreet for the latest stock market news and financial investment headlines.

Elan to Highlight Tysabri Data in Crohn’s Disease at the American...

Tue, 20 Oct 2009 01:00:00 GMT

Elan Corporation, plc (NYSE: ELN) and Biogen Idec (NASDQ: BIIB) today announced multiple presentations at the American College of Gastroenterology (ACG) Annual Scientific Meeting, taking place October 23-28 in San Dieg

Pure Elan II lands - mirror.co.uk

Wed, 14 Oct 2009 12:00:22 GMT

The Pure Sensia might tickle your lust for pricey gadget candy, but the new Pure Elan II will satisfy those of you whose wallet cant quite match your tech fantasies. Its full off the usual Pure goodies and wont cause you to come over all guilty when your better half quizzes you

FRANCE - Avenir et al. invest EUR 2.5m into Elan

Mon, 05 Oct 2009 11:16:00 GMT

A consortium comprising Avenir Entreprises, Siparex and NCI Gestion has acquired a stake in organic product distributor Elan Nature, making an equity investment ofEUR 2

US feds subpoena Elan for brain virus reports | R&D Mag

Tue, 29 Sep 2009 00:00:00 GMT

US regulators subpoena documents of brain disease with drugmaker Elan' s Tysabri

Elan Alters J&J Pact

Fri, 18 Sep 2009 13:10:00 GMT

Elan Alters J&J Pact. Pharmaceuticals: New deal maintains partnership with Biogen Idec, cuts what Johnson & Johnson will pay.

J&J Alzheimer's Deal Includes Taking Stake in Elan

Thu, 17 Sep 2009 22:04:03 GMT

A newly formed subsidiary of Johnson & Johnson bought substantially all of the assets and rights owned by Elan in an Alzheimer’s disease program, the two companies announced on Thursday, and J&J will take a stake in Elan.

Johnson & Johnson Closes Deal For Elan

Thu, 17 Sep 2009 15:22:00 GMT

J&J on Thursday closed its deal to buy a stake in Elan for $885 million and obtain rights to the biotech company's Alzheimer's disease treatment program.